AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00230100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mixed-gender Group Drug Counseling
Description: Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
Study NCT04449224 — intervention group
Intervention type: DRUG
Intervention: Adalimuab, Etanercept, Tocilizumab, or Abatacept
Description: A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
Study NCT04449224 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib or Baricitinib
Description: A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
Study NCT01800435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aPCC, aPCC + TXA
Description: Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
Study NCT01800435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFVIIa, rFVIIa + TXA
Description: NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
Study NCT03527784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietene Macro
Description: Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.
Study NCT03527784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietex Parastomal
Description: Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.
Study NCT03527784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamesh IPST
Description: Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
Study NCT04843280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FORCE therapeutics (physical therapy)
Description: 6 weeks of internet based physical therapy following arthroscopic knee surgery
Study NCT04843280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Outpatient Physical Therapy
Description: 6 weeks of outpatient physical therapy following arthroscopic knee surgery
Study NCT00399529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic GM-CSF-secreting breast cancer vaccine
Description: the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
Study NCT00399529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
Study NCT00399529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
Study NCT03435380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient activation
Description: Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
Study NCT03435380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient activation
Description: Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
Study NCT03435380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary care physician activation
Description: Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.
Study NCT03435380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Mailed educational materials.
Study NCT03435380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Mailed educational materials.
Study NCT00115934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blalock-Taussig pulmonary artery shunt
Description: Performed at stage I palliative surgery for babies born with HLHS
Study NCT00115934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular to pulmonary artery shunt
Description: Performed at stage I palliative surgery for babies born with HLHS
Study NCT04009889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: capsule containing a probiotic blend of 5 different Lactobacilli
Description: n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
Study NCT04009889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.
Description: n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
Study NCT01021267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saw palmetto berry extract
Description: 1x daily 1 capsule containing 320mg lipophilic extract
Study NCT02862119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FFR Treatment Arm
Description: Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
Study NCT02862119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment Arm
Description: Initial Conservative management of non-culprit lesions during index hospital admission
Study NCT01394159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 22G ProCore biopsy needle
Description: Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.
Study NCT01394159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 22G standard FNA needle
Description: Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
Study NCT02073474 — intervention group
Intervention type: DRUG
Intervention: Sativex®
Description: Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
Study NCT03178409 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Removal of a part of the liver
Study NCT00988637 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen
Description: Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
Study NCT00988637 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clobex® Spray morning and Vectical™ Ointment evening regimen
Description: Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
Study NCT03462589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
Study NCT03462589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SY-008
Description: The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
Study NCT02354885 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tranexamic Acid
Description: Coagulation Management / Efficiency
Study NCT04614636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
Study NCT04614636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning Agent
Study NCT04614636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent
Study NCT04614636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Monoclonal Antibody, CD38, Anti-CD38
Study NCT04614636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Monoclonal Antibody
Study NCT01531075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ENGERIX-B (HBV Vaccine)
Description: ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
Study NCT01531075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac
Description: Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
Study NCT00592813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Strong for Life
Description: The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars.
Study NCT00592813 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cardiovascular nutrition education
Description: administered as an attention control intervention using home visits, phone calls and mail-outs of information
Study NCT00933881 — intervention group
Intervention type: OTHER
Intervention: Determining a change in heart rate variability post delivery of the baby
Description: Determining a change in heart rate variability post delivery of the baby
Study NCT01057927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: OC000459 capsules 2x100mg BID for 28 days
Study NCT01057927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
Study NCT01077817 — intervention group
Intervention type: DRUG
Intervention: Alendronate
Study NCT01077817 — intervention group
Intervention type: DRUG
Intervention: Etidronate
Study NCT01598636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral tibial tunnel
Description: To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
Study NCT01269853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle
Study NCT01269853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle
Study NCT00855686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 20mg once daily oral dose
Study NCT00855686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose
Study NCT00848627 — intervention group
Intervention type: OTHER
Intervention: Specimen and questionnaires only
Description: Specimen and questionnaires only
Study NCT01622413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: joimax TESSYS
Description: Transforaminal Endoscopic Surgery System
Study NCT01622413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdiscectomy
Description: Standard procedure for disc surgery
Study NCT02867566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI301 plus CHOP
Description: Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
Study NCT02867566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab plus CHOP
Description: Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
Study NCT02896699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Intervention Group
Study NCT02896699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Study NCT00739765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: 14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
Study NCT00739765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
Study NCT00739765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Description: Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
Study NCT01968226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] RDG-K5
Description: Up to fifteen (15) subjects with carotid stenosis >50% who are undergoing planned carotid endarterectomy will be imaged under PET with \[F-18\] RDG-K5
Study NCT02010138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: small-extent peeling
Description: The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
Study NCT02010138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: large-extent peeling
Description: The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
Study NCT02456506 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated IMRT
Study NCT02456506 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fraction IMRT
Study NCT03461575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU007
Description: cyclosporine 0.02%, trehalose 3%
Study NCT03461575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: cyclosporine 0.05%
Study NCT02009566 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Abdominal radiographs with microfabricated tags
Description: Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
Study NCT00151177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive continuous positive airway pressure ventilation
Study NCT00151177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP-treatment
Description: night time CPAP-mask ventilation
Study NCT03461575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moisview
Description: trehalose 3%
Study NCT01077817 — intervention group
Intervention type: DRUG
Intervention: Ibandronate
Study NCT01077817 — intervention group
Intervention type: DRUG
Intervention: Risedronate
Study NCT01077817 — intervention group
Intervention type: DRUG
Intervention: Raloxifene
Study NCT00362817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
Study NCT00362817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
Study NCT01294566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322888
Description: 1 mg, 5 mg or 25 mg capsule
Study NCT01294566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsules
Study NCT02075606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide acetate
Description: Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
Study NCT04510129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
Study NCT00151177 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: CPAP-treatment
Description: night time CPAP-mask ventilation
Study NCT03044444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: citrus extract
Description: Participants will receive either a low or high dose citrus extract
Study NCT03044444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants will receive 500mg of maltodextrin
Study NCT02908711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% ropivacaine
Description: Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
Study NCT03070626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOp®
Description: No preoperative drink.
Study NCT01093014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-force muscle stimulation
Description: Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
Study NCT01093014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-force muscle stimulation
Description: Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.